Aerial view of the Viking Jupiter cruise ship anchored in the port of Montevideo, on January 5, 2022. Ivan Pisarenko | AFP | Getty ImagesViking is not your typical cruise operator.Aboard its smaller, upscale vessels, you won't find any kids. In fact, the cruise line doesn't hide the fact that...
The BlackRock logo is displayed at the company's headquarters in New York City on Nov. 14, 2022.Leonardo Munoz | Getty ImagesAsset manager BlackRock will launch an investment platform in Riyadh with the help of a $5 billion anchor investment from Saudi Arabia's Public Investment Fund, the kingdom's sovereign wealth...
Check out the companies making headlines in midday trading: New York Community Bank — Shares of the beaten-down regional bank popped more than 31% after CEO Joseph Otting said in a release , "we have a clear path to profitability over the following two years." The bank on Wednesday...
Nearly a dozen analysts have either slashed their price targets or downgraded Starbucks after its disappointing quarterly report, viewing existing headwinds as a longer-term issue for the coffee chain. Starbucks' fiscal second-quarter earnings and revenue fell short of analyst estimates, driven by a surprise decline in same-store sales. After...
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Wednesday' key moments. U.S. stocks were mixed Wednesday as Wall Street prepared for the Federal Reserve's next policy decision in the afternoon. Fed chief Jerome Powell is...
Jim Cramer on Wednesday blasted Starbucks CEO Laxman Narasimhan in a CNBC interview after the coffee giant delivered a terrible quarter and a guidance miss. With Starbucks shares down more than 15% following Tuesday evening's quarterly release and conference call, Jim asked Narasimhan in an interview on CNBC why...
Jakub Porzycki | Nurphoto | Getty ImagesPfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefiting from its broad cost-cutting program, a smaller-than-feared drop in sales of its Covid antiviral pill Paxlovid and strong non-Covid product sales.The company now expects to book adjusted...